Showing results (81-90 of 170) with videos related to
Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working PartyS J Proctor, P Taylor, P Donnan, et al.Cytokine|March 1, 1994
Monoclonal anti-TNF-alpha suppresses graft vs host disease reactions in an in vitro human skin modelA M Dickinson, L Sviland, G Jackson, et al.Clinical Oncology (Royal College of Radiologists (Great Britain))|October 19, 2004
Lymphoma presenting as a parotid tumour: a population-based study of diagnosis, treatment and outcome on behalf of the Scotland and Newcastle Lymphoma GroupC W Tiplady, P R A Taylor, J White, et al.Blood|October 1, 1992
Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcomeP R Taylor, M M Reid, N Bown, et al.Bone Marrow Transplantation|February 1, 1990
An in vitro predictive test for clinical graft-versus-host disease in allogeneic bone marrow transplant recipientsL Sviland, A M Dickinson, P J Carey, et al.The Quarterly Journal of Medicine|January 1, 1980
Intracranial disease in non-Hodgkin's lymphomaG S Venables, S J Proctor, D Bates, et al.Clinical Science (London, England : 1979)|July 1, 1984
The relationship between human adipocyte and monocyte insulin bindingR Taylor, S J Proctor, O James, et al.Chemical Communications (Cambridge, England)|June 15, 2016
Carbene-catalyzed desymmetrization of 1,3-diols: access to optically enriched tertiary alkyl chloridesBao-Sheng Li, Yuhuang Wang, Rupert S J Proctor, et al.Clinical Immunology and Immunopathology|November 1, 1986
Defective in vitro immunoglobulin production in response to pokeweed mitogen in patients with Hodgkin's disease pretreatment and in remissionA M Dickinson, S M McLachlan, E A Jacobs, et al.British Journal of Cancer|February 1, 1993
Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma GroupP R Taylor, G H Jackson, A L Lennard, et al.Pageof 17